Editor-in-chief Jonah Comstock welcomes back returning guest Dr Jennifer Jones-McMeans, divisional vice president for global affairs for Abbott’s vascular business.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh